Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-gremlin-1 monoclonal antibody UCB6114

A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, anti-gremlin-1 antibody UCB6114 specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-GREM1 antibody monoclonal UCB6114
Code name:	UCB 6114 UCB-6114 UCB6114

anti-gremlin-1 monoclonal antibody UCB6114

Search NCI's Drug Dictionary